Pharmacoengineering and Molecular Pharmaceutics
Delivering new methods of drug delivery to optimize therapeutic efficacy of drugs and vaccines
The Division of Pharmacoengineering and Molecular Pharmaceutics (DPMP) is engaged in research and education in drug delivery options to optimize the therapeutic efficacy of pharmacologically and immunologically active agents. It is a multidisciplinary endeavor requiring knowledge in pharmaceutics, chemistry, engineering, biochemistry, biologics, pharmacokinetics, drug metabolism, and biology.
The DPMP faculty is a highly collaborative and entrepreneurial group; they have applied over 18 patents based on their research, and established seven new pharmaceutical and biotech companies in recent years. Several are members of the UNC Lineberger Comprehensive Cancer Center, which offers a wide array of core facilities that support their research activities.
DPMP focuses on training the next generation of researchers specializing in targeted drug delivery that will ensure optimal efficacy of pharmacologically and immunologically active agents.
Two emerging areas in which we are engaging our students are pharmacoengineering and molecular pharmaceutics.
You can learn more about our PhD in Pharmaceutical Sciences program here.
You can learn more about our Postdoctoral Fellowship program here.
Our research focuses on targeted drug delivery that will ensure optimal efficacy of pharmacologically and immunologically active agents. We conduct multidisciplinary research using knowledge in:
- chemistry: physical-chemical aspects of drug molecules, polymer sciences, analytical chemistry
- engineering: nanotechnology, biophysics, mass transport and thermodynamics of drug molecules
- biopharmaceutics: pharmacokinetics, drug metabolism
- biochemistry: immunology, genetics, drug mechanism of action
- biology: cell and virus based platforms, infectious diseases, neurology
You can learn more about our current research here.
You can learn more about our faculty labs here.
For all other questions about the Division of Pharmacoengineering and Molecular Pharmaceutics, contact: